Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

EXITED $ABX WITH PROFIT AS THE TRAILING STOP HIT AT $36.11

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

NOW WE HAVE BIGGER GAINS ON $ABX. TRAIL A TIGHTER STOP TO PROTECT PROFITS

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

TAKING PARTIAL PROFITS ON $ABX RIGHT HERE AT $37.27 AND TIGHTENING THE STOP ON THE REST

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

EXITING $BCRX ( BIOCRYST ) WITH PROFIT

Based on ZYX Change Method, we shorted flu stocks. We have now taken profits on all of these stocks with the exception of $BCRX. Our proprietary money flow indicators are beginning to turn up, therefore ZYX Change Method discipline dictates an exit. For performance tracking purposes, we will use Friday’s closing price of $6.90.for buy to cover. We overstayed in the position as the stock traded as low as $5.55 since we initiated the short position. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE

Read More »

EXITING $AVAV (AEROVIRONMENT) WITH PROFIT

We are buying to cover $AVAV. Friday’s closing price is $25.33. Our original short was based on the thesis that drone business has become more competitive and margins are declining while the Wall Street stays enamored with the apparent sexiness of drones killing terrorists. FY2011 defense budget submission creates more uncertainties for $AVAV. Based alone on its defense business, we would have stayed short on the stock. However, based on the hype surrounding home charging stations for LEAF electric car from Nissan, it is prudent to take advantage of recent sell off and cover the position. Earlier, we took advantage

Read More »

UPDATE ON OPEN INDIVIDUAL STOCK POSITIONS

We are exiting $BCRX and $AVAV; please see separate posts for the reasons. We are short on $ACOR with average price of $30.28. Our thesis has not changed in that Ampyra is not a very good drug, although Wall Street has termed it a blockbuster drug. . In the short term, the bulls may be right. For the first time MS patients with difficulty in walking have hope. MS patients, in general tend to be very knowledgeable about new drugs and as such they are likely to demand that neurologists prescribe Ampyra. Anecdotal evidence supports that neurologists will initially cede

Read More »

SHORT SELL ON $ABX (BARRICK GOLD)

Consider short sell on $ABX with scale ins right here at $39.45. Stop zone over $41.16. With IMF sales of gold looming and dollar getting stronger, macro picture is not favorable in the very short term. After earnings this morning the stock is technically overbought. There was nothing in the earnings to prompt the run we are seeing. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions:

Read More »

WE WILL ADD TO US JUNK BOND ALLOCATION ON DIPS

Our Multi-Asset Global Allocation Model has been 20% long on US junk bonds since Oct 26, 2009. We have also been 10% long on US Senior Bank Loans. This allocation has not only contributed high single digits yield bu, but also capital gains. Senior Bank Loans have provided 15% capital gains over this period of less than four months. Recently, some of the capital gains on high yield bonds have been lost. According to Lipper, last week nearly $1 billion was withdrawn from US funds that hold high yield bonds. Spreads from US treasuries have widened by more than 100

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content